Download PDF

1. Company Snapshot

1.a. Company Description

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants.


In addition, it distributes human cell, tissue, and cellular and tissue-based products.Globus Medical, Inc.was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Show Full description

1.b. Last Insights on GMED

Globus Medical's recent performance was driven by strong Q3 earnings, beating estimates with $1.18 per share, and a solid revenue outlook. The company's impressive sales growth, with a 25.2% increase in Q4 2025, and a 16.5% rise in full-year 2025 sales, contributed to its positive momentum. Additionally, a "golden cross" event, where its 50-day moving average broke out above its 200-day moving average, signaled a potential buy opportunity. Brokerages have a "Moderate Buy" rating on the stock, with eight issuing a buy recommendation.

1.c. Company Highlights

2. Globus Medical's Q4 2025 Earnings: A Strong Finish to a Record Year

Globus Medical reported a robust Q4 2025, with revenue reaching $826.4 million, representing a 25.7% as-reported growth and 24.7% on a constant currency basis. GAAP net income was $140.6 million, resulting in $1.03 of fully diluted earnings per share, slightly below estimates of $1.06. Non-GAAP net income was $174.6 million, delivering $1.28 of fully diluted non-GAAP earnings per share, a 52.1% increase over the prior year quarter. The company's adjusted gross profit margin expanded to 69.2%, driven by favorable sales mix, sales leverage, and synergy execution.

Publication Date: Feb -26

📋 Highlights
  • Full-Year Revenue Growth: 2025 revenue reached $2.939 billion, up 16.7% (as-reported) and 16.2% (constant currency) from 2024.
  • Q4 Non-GAAP EPS Surge: Fully diluted non-GAAP earnings per share rose 52.1% YoY to $1.28, driven by $174.6 million in non-GAAP net income.
  • Adjusted Gross Profit Margin Expansion: Q4 adjusted gross margin hit 69.2% (vs. 67.1% in 2024), with full-year margin at 68.1% (vs. 67.4% in 2024).
  • Enabling Technologies Record Performance: Generated $55.6 million in Q4 revenue, a 18.5% YoY increase, with record sales for ExcelsiusGPS robotic systems.
  • 2026 Guidance Raised: Non-GAAP EPS guidance lifted to $4.40–$4.50 (up from $4.30–$4.40), implying 10.6–13.1% growth over 2025.

Segment Performance

The U.S. Spine business continued its above-market growth trend, achieving 9.7% as-reported growth. Enabling Technologies revenue reached a record $55.6 million, growing 18.5% as reported. International revenue for the legacy Globus business was $150.1 million, growing 10.9% as reported and 6.5% on a constant currency basis. The company's diversified portfolio and successful integrations of recent mergers and acquisitions drove the strong performance.

Guidance and Outlook

Globus Medical reiterated its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and increased its guidance for non-GAAP fully diluted earnings per share to $4.40 to $4.50. The company expects to drive growth through new product launches, conversion of competitive reps, and implant pull-through. As Keith Pfeil stated, "We're excited about the opportunities ahead." The guidance implies a revenue growth rate of 8.2% to 9.6% and non-GAAP EPS growth of 10.6% to 13.1%.

Valuation

With a P/E Ratio of 24.18, P/B Ratio of 2.84, and EV/EBITDA of 15.26, Globus Medical's valuation multiples indicate a premium relative to its historical averages. However, the company's strong growth prospects, driven by its diversified portfolio and successful integrations, may justify the premium. Analysts estimate next year's revenue growth at 5.8%, which is relatively conservative compared to the company's historical performance.

Conclusion on Financial Health

The company's cash, cash equivalents, and marketable securities stood at $629.1 million at December 31, 2025. The decline in cash is driven by the repayment of outstanding convertible debt, the acquisition of Nevro, and share repurchases. With a Net Debt / EBITDA ratio of -0.5, Globus Medical's financial health remains robust, allowing it to invest in growth initiatives and return value to shareholders.

3. NewsRoom

Card image cap

5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside

Mar -10

Source: zacks.com

Card image cap

Bears are Losing Control Over Globus Medical (GMED), Here's Why It's a 'Buy' Now

Mar -09

Source: zacks.com

Card image cap

Elo Mutual Pension Insurance Co Has $1.30 Million Stake in Globus Medical, Inc. $GMED

Mar -06

Source: defenseworld.net

Card image cap

Is This the Right Time to Add Globus Medical Stock to Your Portfolio?

Mar -05

Source: zacks.com

Card image cap

Globus Medical (GMED) Upgraded to Strong Buy: What Does It Mean for the Stock?

Mar -04

Source: zacks.com

Card image cap

New Strong Buy Stocks for March 4th

Mar -04

Source: zacks.com

Card image cap

GE Aerospace, Nuclear Play Lead 5 Stocks Near Buy Points

Feb -28

Source: investors.com

Card image cap

Here's What Key Metrics Tell Us About Globus Medical (GMED) Q4 Earnings

Feb -25

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.15%)

6. Segments

Musculoskeletal Solutions

Expected Growth: 12.0%

Globus Medical's Musculoskeletal Solutions segment growth is driven by increasing demand for minimally invasive spine procedures, expansion into emerging markets, and strategic product launches. Additionally, the company's focus on innovation, strong sales force, and growing presence in the orthopedic market contribute to its 12.0% growth.

Enabling Technologies

Expected Growth: 14.0%

Globus Medical's Enabling Technologies segment growth of 14.0% is driven by increasing adoption of robotic navigation systems, expansion into new markets, and strategic partnerships. Additionally, advancements in artificial intelligence and machine learning are enhancing the accuracy and efficiency of spinal procedures, further fueling growth.

7. Detailed Products

Spine Products

Globus Medical's spine products include a comprehensive portfolio of innovative implants, instruments, and biologics for the treatment of various spinal disorders and deformities.

Orthopedic Trauma Products

Globus Medical's orthopedic trauma products offer a range of implants and instruments for the treatment of fractures, osteotomies, and bone defects.

Joint Reconstruction Products

Globus Medical's joint reconstruction products include a range of implants and instruments for total joint replacement, partial joint replacement, and osteotomies.

Robotics and Navigation

Globus Medical's robotics and navigation products provide surgeons with advanced visualization and navigation tools for spinal and orthopedic procedures.

Biologics

Globus Medical's biologics products include a range of allografts, demineralized bone matrices, and synthetic bone graft substitutes.

8. Globus Medical, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Globus Medical, Inc. operates in the medical device industry, where substitutes are limited. However, the company faces competition from alternative treatments and procedures, which could impact its market share.

Bargaining Power Of Customers

Globus Medical, Inc. sells its products to hospitals and medical professionals, who have limited bargaining power due to the specialized nature of the products.

Bargaining Power Of Suppliers

Globus Medical, Inc. relies on a network of suppliers for raw materials and components. While the company has some bargaining power, suppliers also have some leverage due to the specialized nature of the products.

Threat Of New Entrants

The medical device industry has high barriers to entry, including regulatory hurdles and significant research and development investments. This limits the threat of new entrants to Globus Medical, Inc.'s market.

Intensity Of Rivalry

The medical device industry is highly competitive, with several established players competing for market share. Globus Medical, Inc. faces intense competition from companies such as Medtronic, Stryker, and Johnson & Johnson.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 9.70%
Debt Cost 5.21%
Equity Weight 90.30%
Equity Cost 9.50%
WACC 9.09%
Leverage 10.74%

11. Quality Control: Globus Medical, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
TransMedics

A-Score: 4.8/10

Value: 1.0

Growth: 9.0

Quality: 6.7

Yield: 0.0

Momentum: 9.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Globus Medical

A-Score: 4.4/10

Value: 3.0

Growth: 6.3

Quality: 7.2

Yield: 0.0

Momentum: 6.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Align Technology

A-Score: 3.6/10

Value: 3.6

Growth: 5.3

Quality: 7.2

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Bruker

A-Score: 3.5/10

Value: 5.9

Growth: 5.2

Quality: 2.9

Yield: 0.0

Momentum: 3.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Integer

A-Score: 3.2/10

Value: 4.5

Growth: 5.1

Quality: 4.7

Yield: 0.0

Momentum: 0.5

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Tandem Diabetes Care

A-Score: 3.1/10

Value: 7.2

Growth: 3.6

Quality: 3.6

Yield: 0.0

Momentum: 2.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

86.65$

Current Price

86.65$

Potential

-0.00%

Expected Cash-Flows